Brain+ (BRAINP) Investor Update summary

Product and market strategy

• Focused on health tech solutions for dementia, with CST Assistant as the first product targeting therapists delivering Cognitive Stimulation Therapy (CST), a globally recommended non-drug therapy for dementia.

• CST Assistant automates session preparation, standardizes quality, and has shown to reduce therapist preparation time by 50%, validated by usability trials and endorsements from key opinion leaders.

• The U.K. is the primary target market due to high clinical recognition of CST and system-level mandates for its use, with initial rollout in Denmark for live market testing.

Go-to-market and sales approach

• Bottom-up strategy includes partnerships with major charities like Age UK and targeting early adopter NHS trusts already familiar with CST.

• Top-down strategy leverages regulatory approval as a Class I medical device, enabling medical claims and higher pricing, and aims for regional reimbursement through Integrated Care Systems.

• Commercial partner Quiddity Health supports NHS penetration, with plans for rapid outreach and sales pipeline expansion post-launch.

Financial outlook and funding

• Current unit rights issue aims to fund operations through Q1 2026, with proceeds from both share subscriptions and warrants.

• 60% of the rights issue is already secured via commitments from management, board, and major shareholders.

• Full subscription and warrant exercise could fund the company to break-even, expected in 2026, with additional options from grants and private equity.